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Abstract
Background: miRNAs play crucial role in the progression of K-Ras-mutated nonsmall cell lung cancer (NSCLC).
However, most studies have focused on miRNAs that target K-Ras. Here, we investigated miRNAs regulated by
mutant K-Ras and their functions.
Methods: miRNAs regulated by mutant K-Ras were screened using miRNA arrays. miR-199b expression levels were
measured by qRT-PCR. The protein expression levels were measured using Western blot and
immunohistochemistry. The effects of miR-199b on NSCLC were examined both in vitro and in vivo by
overexpressing or inhibiting miR-199b. DNA methylation was measured by bisulfite sequencing.
Results: An inverse correlation was observed between K-Ras mutation status and miR-199b levels in NSCLC
specimens and cell lines. The inhibition of miR-199b stimulated NSCLC growth and metastasis, while restoration of
miR-199b suppressed K-Ras mutation-driven lung tumorigenesis as well as K-Ras-mutated NSCLC growth and
metastasis. miR-199b inactivated ERK and Akt pathways by targeting K-Ras, KSR2, PIK3R1, Akt1, and Rheb1.
Furthermore, we determined that mutant K-Ras inhibits miR-199b expression by increasing miR-199b promoter
methylation.
Conclusion: Our findings suggest that mutant K-Ras plays an oncogenic role through downregulating miR-199b in
NSCLC and that overexpression of miR-199b is a novel strategy for the treatment of K-Ras-mutated NSCLC.
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Background
Lung cancer is the leading cause of cancer-related death
worldwide; moreover, nonsmall-cell lung cancer (NSCLC)
is the predominant type, as it accounts for 80% of all lung
cancers [1]. The initiation of lung cancer is caused by a
number of factors, including genetic alterations such as
mutations in K-Ras, epidermal growth factor receptor
(EGFR), anaplastic lymphoma kinase (ALK), phosphoino-
sitide 3-kinase (PI3K), and BRAF [2–4]. Among these,
K-Ras is the most frequently mutated oncogene found in
NSCLC, 29% NSCLC patients have K-Ras mutation [5].
Notably, K-Ras mutations are not only related to cancer
initiation; they also promote cancer progression, like me-
tastasis [6] and therapeutic resistance [7] Thus, K-Ras is a
high-priority therapeutic target, but despite the decades of
effort, no targeted therapy is clinically available for
K-Ras-mutated cancers [8].
MicroRNAs (miRNAs) are ~ 20–23 nucleotide
single-stranded small noncoding RNAs that negatively
regulate target gene expression by promoting the deg-
radation or inhibiting the translation of the mRNA of
target genes. Dysregulated expression of miRNAs is
found in most types of cancers, and these miRNAs can
promote cancer initiation and progression [9]. Interest-
ingly, miRNA dysregulation has been linked to the acti-
vation of certain oncogenes, such as K-Ras mutations
[10]. Recent studies showed that overexpression or in-
hibition of certain miRNAs can significantly suppress
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the progression of K-Ras-mutated NSCLC by targeting
K-Ras [1, 8], suggesting that artificial modulation of
certain miRNAs that are associated with K-Ras-driven
cancers may be a useful therapeutic strategy for treating
K-Ras-mutated NSCLC. However, most studies have fo-
cused on finding miRNAs that can target K-Ras.
Here, we report that level of miR-199b was inversely
correlated with K-Ras mutations in NSCLC, and mutant
K-Ras inhibits miR-199b expression by increasing
miR-199b promoter methylation. Importantly, restor-
ation of miR-199b inhibited K-Ras-mutated NSCLC
growth, metastasis and K-Ras mutation-driven lung
tumorigenesis through the inhibition of Akt and ERK
signaling by directly targeting K-Ras and multiple coacti-
vators of Akt and ERK signaling. Our results suggest
that K-Ras mutations cause lung tumorigenesis and pro-
gression partly through the inhibition of miR-199b
expression and that restoring miR-199b expression may




In Situ Cell Death Detection Kit, 5-azacytidinecytidine,
anti-caspase 3 antibody, anti-actin antibody, anti-p70S6K
(Thr389), fetal bovine serum (FBS) and cell culture
medium were obtained from Sigma (St. Louis, MO).
Dual-Luciferase Assay Kit and Invasion Assay Kit were
purchased from Promega (Madison, WI) and BD Biosci-
ences (San Jose, CA), respectively. TRIzol, cDNA reverse
transcription kit, miRNA luciferase reporter vector, primer
sets for miR-199b and U6, Lipofectamine 2000, SYBR
Green PCR kit, miR-199b mimics, control oligonucleo-
tides, and miRNA assay kit were purchased from Life
Technologies (Carlsbad, CA). Human miRNA Array v2.0
and Human genome U133 Plus 2 array were obtained
from Arraystar (Rockville, MD) and Affymetrix (Santa
Clara, CA), respectively. shRNA of K-Ras, Renilla Lucifer-
ase, and K-Ras (G12D) expression constructs were kindly
provided by Dr. Cheng (Moffitt Cancer Center). Anti-
bodies against K-Ras, KSR2, PIK3R1, Rheb1, Akt1,
phospho-Akt (Ser473), phospho-ERK (Thr202/Tyr204),
phospho-mTOR (Ser2448), and Ki-67 were purchased
from Abcam (Cambridge, MA). K-Ras (G12D) antibody
was obtained from Cell Signaling Technology, Inc.
Cell culture and specimens
H157, H1975, H2172, HCC827, H2122, H441, A549 and
H460 were purchased from American Type Culture Col-
lection (Manassas, VA). PC-9 and H125 were kindly pro-
vided by Dr. Shen (Jilin University, China). All cell lines
were cultured in Dulbecco’s Modified Eagle Medium
supplemented with 10% FBS. NSCLC specimens were
collected before treatment from patients with newly
diagnosed NSCLC at Daping Hospital, Third Military
Medical University. This experiment was approved by
the ethical review committees of Daping Hospital, Third
Military Medical University.
RNA isolation and analysis
Total RNA was isolated from tissues and cells using
TRIzol according to the manufacturer’s instructions.
miR-199b and U6 were analyzed using a TaqMan
miRNA Assay Kit. The relative expression of miR-199b
was normalized against U6 expression using the 2-△Ct
method, and the miR-199b expression fold-change in
NSCLC tissue was matched to nontumor control sam-
ples for evaluation. For other genes, RT and PCR were
performed with the cDNA RT Kit and SYBR Green PCR
Kit, respectively. Primer sequences are listed in Add-
itional file 1: Table S1. miRNAs affected by K-Ras were
detected using Human miRNA Array v2.0 and genes
affected by miR-199b were detected using Human gen-
ome U133 Plus 2 array.
Luciferase reporter assay
The 3`-UTR segments of genes that were predicted to
interact with miR-199b were amplified by PCR from hu-
man genomic DNA and inserted into MluIand HindIII
sites of the miRNA Expression Reporter Vector. Lucifer-
ase assay was performed using HEK293 cells as previ-
ously described [11].
Immunoblotting
Western blotting and immunohistochemistry were per-
formed as previously described [12]. Western blot band
intensity was quantified using Image J software (National
Institutes of Health, Bethesda, MD).
Invasion, cell viability and cell proliferation assay
Cells were transfected with the indicated oligonucleo-
tides for 24 h and then subjected to analysis. Invasion,
cell viability and cell proliferation assays were performed
as previously described [11].
Colony formation assay
After 24 h of oligonucleotide transfection, cells were
trypsinized and resuspended in 0.5 ml 0.35% agar in
growth medium at a density of 2500 cells/well (6-well
plate). Then, the agar-cell mixture was plated on the top
of a solid layer of 0.8% agar in growth medium. Colonies
were counted 12 days later.
Animal experiments
miR-199b effects on K-Ras mutation-driven lung tumori-
genesis were examined using 6-week-old female K-RasLA1
transgenic mice at Seoul National University, Korea.
miR-199b expression plasmids or empty vectors were
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mixed with the gene delivery nanoparticle, PCAmHn, as
previously described [13], and this mixture was then deliv-
ered to mice using an aerosol-based, nose-only exposure
chamber system as previously described [14]. Briefly, mice
were randomly divided into three treatment groups (6
mice per group), and then mice were exposed to aerosol
containing 10mg of PCAmHn with or without 1mg plas-
mid (miR-199b plasmid or empty vector). K-RasLA1 mice
were exposed to aerosol twice a week for one month.
For the subcutaneous tumor growth assay, 2 × 106 in-
dicated cells in 0.1 ml of phosphate-buffered saline were
subcutaneously injected into 6-week-old male nude
mice. One month after cell injection, these mice were
sacrificed.
For lung metastasis experiments, 5 × 105 indicated
cells were suspended in 0.1 ml of PBS and injected into
the lateral tail vein of 6-week-old male nude mice. One
month after injection, mice were sacrificed, and lung
surface tumor foci were counted. This experiment was
conducted at the Daping Hospital and Research Institute
of Surgery, Third Military Medical University. All animal
experiments were approved by the Animal Care and Use
Committees of the appropriate institutions.
DNA methylation assay
Genomic DNA was isolated using the QIAGEN DNA
extraction kit, and 1 μg of genomic DNA was treated
with sodium bisulfite. The bisulfite-treated DNA was
desalted and eluted in 40 μl of elution buffer; then, 2 μl
of DNA was amplified with the forward primer
5′-TTAAAGAGGTTGGGTATGAG-3′ and the reverse
primer 5′-ATCCTCTAATCCATCCAAAC-3′. PCR
products were ligated into the TA cloning vector, and
the DNA sequences were determined using the follow-
ing primers: forward primer: 5′-GGAGGAGAGGAGGA
AGTT-3′; reverse primer: 5′-CCAACCTATATCCC
CCTAAC-3′.
Statistical analysis
All data are presented as the mean ± standard deviation,
and significant differences between treatment groups
were analyzed by Student’s t-test or one-way analysis of
variance (ANOVA) and Duncan’s multiple range test
using SAS statistical software version 6.12 (SAS Insti-
tute). Differences were considered statistically significant
at a p value of less than 0.05.
Results
miR-199b expression was negatively regulated by mutant
K-Ras in NSCLC
To identify miRNAs that are regulated by mutant
K-Ras in NSCLC, we performed miRNA array assays
using the K-Ras (G12D)-overexpressing NSCLC cell
lines H1975 and H522, as well as their vector control
cells. As shown in Fig. 1a, we detected a total of 46
miRNAs that were significantly decreased by K-Ras
(G12D) overexpression in both NSCLC cell lines
compared to the respective control cells. Among
them, miR-199b was the most significantly inhibited.
Consistent with miRNA array results, clinical samples
and NSCLC cell line analysis results showed that
miR-199b was dramatically decreased in K-Ras-mu-
tated NSCLC specimens and cell lines compared to
wild- type K-Ras NSCLC specimens and cell lines
(Fig. 1b and c). Additionally, we demonstrated
decreased expression of miR-199b in K-Ras-mutated
NSCLC specimens compared to their adjacent tissues
(Fig. 1d). However, we did not observe differences be-
tween adjacent tissues and tumors in K-Ras wild-type
NSCLC patients (Fig. 1e). These data strongly sug-
gested that mutant K-Ras may be involved in the
negative regulation of miR-199b in NSCLC. To test
this hypothesis, we measured the expression of
miR-199b after knockdown or overexpression of mu-
tant K-Ras (G12D) (Additional file 1: Figure S1) in
NSCLC cells with mutant or wild-type K-Ras, respect-
ively. Our data show that knockdown of K-Ras signifi-
cantly increased miR-199b expression, while
overexpression of mutant K-Ras suppressed miR-199b
expression (Fig. 1f and g). Taken together, our results
support the idea that mutant K-Ras suppresses the
expression of miR-199b in NSCLC.
Inhibition of miR-199b significantly contributes to NSCLC
progression
To further validate the effects of downregulated
miR-199b expression on NSCLC progression, we per-
formed cell-based experiments where we expressed anti-
sense oligonucleotides in the high-expressing miR-199b
NSCLC cell lines H522 and H1975. As expected, inhib-
ition of miR-199b (Additional file 1: Figure S2a) strongly
promoted cell proliferation (Fig. 2a), soft agar colony
formation (Fig. 2b) and invasion (Fig. 2c) in both H522
and H1975 cells. To further confirm these in vitro
experimental results in vivo, nude mice were subcutane-
ously inoculated with miR-199b-silenced H522 cells and
the corresponding control cells. Consistent with the in
vitro results, animal experiments showed that inhibition
of miR-199b (Additional file 1: Figure S2b) significantly
stimulated tumor growth (Fig. 2d) and cancer cell prolif-
eration (Fig. 2e) compared to the vector control.
We also investigated the effects of downregulated
miR-199b on lung cancer metastasis by tail vein in-
jection of H522 cells that stably express
miR-199b-antisense oligonucleotides into nude mice,
and we assessed tumor nodule burden after 1 month.
Our data show that inhibition of miR-199b dramatic-
ally increased NSCLC cell lung metastasis (Fig. 2f ).
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These in vivo and in vitro data suggest that
miR-199b may affects clinical outcome of NSCLC
patients. In fact, TCGA dataset analysis showed that
decreased miR-199b expression levels were signifi-
cantly correlated with poor survival rates in patients
with lung adenocarcinoma (Fig. 2g). Taken together,
these findings support a model where inhibition of
miR-199b significantly contributes to NSCLC
progression.
Restoring miR-199b inhibits K-Ras-mutated NSCLC
progression and K-Ras mutation-driven lung
tumorigenesis
Given that the K-Ras mutation inhibits the expression
of miR-199b and that the inhibition of miR-199b pro-
motes NSCLC progression, we hypothesized that re-
storing miR-199b could suppress K-Ras-mutated
NSCLC. Cell-based assays on the K-Ras-mutated
NSCLC cell lines A549 and H2122 with overexpressed
miR-199b (Additional file 1: Figure S2c) showed sig-
nificant suppression of cell proliferation (Fig. 3a), soft
agar colony formation (Fig. 3b) and invasion (Fig. 3c)
in both cell lines. Then, we tested the effects of
miR-199b overexpression on K-Ras-mutated NSCLC
growth in xenograft models that were generated by
stably expressing miR-199b in A549 cells (Additional
file 1: Figure S2d). We found that overexpression of
miR-199b significantly inhibited tumor growth (Fig.
3d) and cancer cell proliferation (Fig. 3e) compared
to the vector control. We also confirmed the in vivo
anti-metastatic effects of miR-199b using a lung me-
tastasis model that was generated by stably expressing
miR-199b in A549 cells. As shown in (Fig. 3f ),
miR-199b-overexpressing A549 cells formed fewer
tumor nodules in the lung than the vector control,
demonstrating that miR-199b can inhibit the metasta-
sis of K-Ras-mutated NSCLC cells.
Next, we investigated the effects of miR-199b on
K-Ras mutation-driven lung tumorigenesis. To verify
the effects of miR-199b on K-Ras mutation-driven lung
tumorigenesis, we used aerosol-based, nose-only expos-
ure methods to deliver miR-199b to the lungs of
K-RasLA1 transgenic mice. To enhance the aerosol gene
delivery efficiency, we used the gene carrier particle
Fig. 1 Mutant K-Ras suppresses miR-199b expression in NSCLC. a Heatmap showing the 46 significantly downregulated miRNAs in K-Ras (G12D)-
overexpressing NSCLC cell lines. b miR-199b expression is downregulated in specimens from NSCLC patients with K-Ras mutations (n = 24)
compared to those from K-Ras wild-type specimens (n = 36). c K-Ras-mutated NSCLC cell lines have lower miR-199b expression levels than NSCLC
cell lines with wild-type K-Ras. d miR-199b was significantly decreased in K-Ras-mutated NSCLC specimens compared to their respective adjacent
tissues (n = 24). e No difference was observed between adjacent tissues and NSCLC tissue from K-Ras wild-type patients (n = 36). f Silencing of K-
Ras increased miR-199b expression in both K-Ras-mutated NSCLC cell lines, A549 and H2122. Cells were transfected with a K-Ras shRNA
expression vector or a scrambled vector for 72 h and then subjected to miR-199b analysis. g Overexpression of mutant K-Ras (G12D) inhibits miR-
199b expression in both K-Ras wild-type NSCLC cell lines, H522 and H1975. Cells were transfected with a K-Ras (G12D) expression vector or an
empty vector for 72 h and then subjected to miR-199b analysis
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PCAmHn. As shown in Additional file 1: Figure S3a, we
delivered a green fluorescent protein (GFP) expression
plasmid with the gene carrier, which significantly en-
hanced the GFP signal compared with plasmid-only
controls, suggesting that PCAmHn is an efficient gene
delivery carrier. In fact, miR-199b expression plasmid
delivery with the gene carrier PCAmHn significantly in-
creased miR-199b levels in the lung tissues of K-RasLA1
transgenic mice compared to the carrier and vector
control groups (Additional file 1: Figure S3b). Notably,
such delivery of miR-199b to the lungs of K-RasLA1
transgenic mice dramatically decreased the numbers of
tumors in the lung (Fig. 3g). Histopathologic examin-
ation also indicated that pulmonary tumor formation
was significantly suppressed by miR-199b delivery (Fig.
3g). In addition, miR-199b delivery significantly inhib-
ited the expression of the cell proliferation marker pro-
tein Ki-67 compared to other groups (Fig. 3h). Taken
together, restoration of miR-199b can suppress K-Ras
mutation-driven lung tumorigenesis, and restoration of
miR-199b may be a useful strategy for treating
K-Ras-mutated NSCLC.
miR-199b targets K-Ras and multiple genes that are
involved in both Akt and ERK signaling activation
To investigate the anticancer mechanism of miR-
199b, we performed gene array analysis using
miR-199b-overexpressing H1299 cells and their con-
trol cells. As shown in Fig. 4a, we detected a total 72
genes that were downregulated more than 1.5-fold in
miR-199b-overexpressing H1299 cells compared to
control cells. Among them, we found that 11 genes
contained putative miR-199b target sites in their
3`-UTRs (www.targetscan.org) (Fig. 4b). Interestingly,
5 of the genes are involved in the activation of the
K-Ras downstream signaling pathway, including
K-Ras, Akt1, Rheb1, PIK3R1 and KSR2 (Fig. 4c). To
test whether miR-199b regulates the expression of
candidate target genes, we examined the expression




Fig. 2 Inhibition of miR-199b stimulates NSCLC progression. a-c Inhibition of miR-199b promotes cell proliferation, soft agar colony formation,
and cell invasion in both H522 and H1975 NSCLC cell lines. Cells were transfected with negative control oligonucleotides (NC) or antisense
oligonucleotides of miR-199b (ASO miR-199b) and were then subjected to cell proliferation, soft agar colony formation and invasion analysis. d-e
Inhibition of miR-199b stimulates tumor growth and cancer cell proliferation in the H522 xenograft model. Using stably expressing miR-199b-
antisense H522 cells or control cells, xenografts were generated in nude mice. One month after cell injection, mice were sacrificed, and the tumor
weights were measured. Cell proliferation was measured using Ki-67 immunohistochemistry in tumor tissues. f Inhibition of miR-199b promotes
NSCLC cell metastasis in vivo. Stably expressing miR-199b-antisense H522 cells or control cells were injected into nude mice by tail vein injection.
The mice were sacrificed 1 month after cell injection, and the tumors on the lung were counted. g Kaplan-Meier analysis of the overall survival of
patients with lung adenocarcinoma for whom overall survival information was available in the TCGA lung cancer data set
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or miR-199b-antisense NSCLC cells. Our results show
that miR-199b negatively regulated the expression of
all candidate genes, as indicated by both the mRNA
(Fig. 4d) and protein levels (Fig. 4e and Additional
file 1: Figure S4a). We also observed downregulation
of miR-199b candidate target genes in the lung tissues
of K-RasLA1 transgenic mice in which miR-199b was
delivered compared to the lungs of control mice (Figs.
4f and Additional file 1: Figure S4b). Furthermore, we
demonstrated a direct interaction between miR-199b
and the 3′-UTR of target genes using a miRNA lucif-
erase reporter assay. We expressed luciferase con-
structs containing the 3′-UTR of miR-199b target
genes. In all cases, luciferase activity was reduced in
the presence of miR-199b mimics (Fig. 4g). In con-
trast, luciferase activity was unchanged in negative
controls in which putative seed sequences were mu-
tated (Fig. 4g).
We then tested whether miR-199b negatively regulates
Akt and ERK signaling in NSCLC. As shown in Fig. 5a
and Additional file 1: Figure S5a, overexpression of
miR-199b significantly inhibited the phosphorylation of
Akt, mTOR, S6K and ERK in NSCLC cell lines, and
cleaved caspase-3 levels increased. Consistent with the
in vitro results, K-RasLA1 transgenic mice experiments
also showed that delivery miR-199b can significantly in-
hibit ERK and Akt signaling activation and induce can-
cer cell apoptosis (Fig. 5b). In contrast, inhibition of
miR-199b significantly stimulated Akt and ERK signaling
in NSCLC cells (Figs. 5c and Additional file 1: Figure
S5b). Taken together, our findings indicated that
miR-199b inhibited Akt and ERK signaling by directly
a
e f g h
b c d
Fig. 3 Overexpression of miR-199b dramatically inhibits K-Ras mutation-driven lung tumorigenesis and progression. a-c Overexpression of miR-
199b inhibited cell proliferation, soft agar colony formation and cell invasion in both K-Ras-mutated NSCLC cell lines, A549 and H2122. Cells were
transfected with negative control oligonucleotides (NC) or miR-199b mimics and then subjected to cell proliferation, soft agar colony formation
and invasion assays. d-e Overexpression of miR-199b inhibited tumor growth and cancer cell proliferation in the A549 xenograft models. Stably
expressing miR-199b A549 and vector control cells were used to generate a xenograft model in nude mice. Tumors were collected 1 month after
cell injection, and the tumor weights were measured. Cell proliferation was analyzed using Ki-67 IHC in tumor tissues. f Overexpression of miR-
199b inhibited NSCLC cell metastasis in vivo. Stably expressing miR-199b A549 or control cells were injected into nude mice by tail vein injection.
The mice were sacrificed 1 month after cell injection, and the tumors on the lung surface were counted. g Aerosol delivery of miR-199b to the
lungs inhibits K-Ras mutation-driven lung tumorigenesis. K-RasLA1 transgenic mice were exposed to a mixture of miR-199b expression plasmid
with the gene carrier (miR-199), gene carrier only (Carrier) or empty plasmid only (vector) using a nose-only aerosol delivery system. Four weeks
after gene delivery, mice were sacrificed, and the number of tumor nodules on the lung surface were counted. h Aerosol delivery of miR-199b
inhibited cancer cell proliferation in lung tumor of K-RasLA1 transgenic mice. The Ki-67 expression was detected using immunohistochemistry
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targeting K-Ras and multiple coactivators of Akt and
ERK signaling in NSCLC.
Mutant K-Ras inhibits miR-199b expression by increasing
miR-199b promoter DNA methylation
Previous studies showed that K-Ras can regulate gene
expression by altering DNA methylation [15] and that
the expression level of miR-199b is determined by its
promoter methylation status [16]. We therefore sus-
pected that mutant K-Ras-dependent suppression of
miR-199b expression in NSCLC cells might be due to
increased methylation in the miR-199b promoter. As ex-
pected, miR-199b expression levels were restored after
treatment with the DNA methylation inhibitor
5-azacytidinecytidine in NSCLC cells containing K-Ras
mutations (Fig. 6a). Consistent with these results, mu-
tant K-Ras-dependent downregulation of miR-199b was
blocked by 5-azacytidinecytidine treatment in wild-type
K-Ras NSCLC cells (Fig. 6b). Moreover, bisulfite
sequencing and quantitative methylation-specific PCR of
the miR-199b CpG island region confirmed that methy-
lation levels of the miR-199b promoter are increased in
NSCLC cells overexpressing mutant K-Ras (Fig. 6c). In
contrast, the silencing of mutant K-Ras decreased
methylation levels (Fig. 6d). These findings indicated
that mutant K-Ras inhibits miR-199b expression by
increasing the methylation of the miR-199b promoter.
Discussion
Downregulated expression of miR-199b has been identi-
fied in several types of tumors, including hepatocellular
carcinoma [17], leukemia [18], glioma [19], ovarian can-
cer [16], colorectal cancer and breast cancer [20, 21].
Dysregulated expression of miR-199b was also detected
in lung cancer previously by several research groups, but
these results are inconsistent. For example, Kim et al.
[22] reported that miR-199b was upregulated in lung




Fig. 4 miR-199b targets several components of the RAS-ERK and PI3K/Akt signaling pathways. a Heatmap showing the 72 downregulated genes
in miR-199b-overexpressing H1299 cells. b Venn diagram showing candidate target genes of miR-199b in NSCLC. Candidate target genes of miR-
199b were indicated using TargetScanHuman from the 72 genes that were downregulated by miR-199b overexpression in H1299 cells. c
Sequence alignment of miR-199b with the 3`-UTR of the K-Ras, PIK3R1 (PI3K p85), Akt1, Rheb and KSR2 genes. d-e miR-199b negatively regulates
the expression of the candidate target genes of miR-199b at both the mRNA and protein levels in NSCLC cells. The mRNA and protein expression
levels of the indicated genes were measured using qRT-PCR and Western blot analysis in stably expressing miR-199b A549 cells and stably
expressing miR-199b-antisense H522 cells. f The expression of candidate target genes of miR-199b was significantly decreased in lung tissues
from miR-199b-delivered K-RasLA1 transgenic mice. The expression levels of the indicated proteins were detected in lung tissues of miR-199b-
delivered K-RasLA1 transgenic mice and their control groups using Western blot analysis. g 3`-UTR luciferase reporter assay for candidate genes of
miR-199b. HEK293 cells were cotransfected with miRNA luciferase reporter plasmid harboring indicated gene mutants or wild-type 3’UTR and
miR-199b mimics or negative oligonucleotides control (NC). After 48 h of transfection, luciferase intensity was assessed
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miR-199b was downregulated in NSCLC. In addition,
the regulatory mechanism of miR-199b in NSCLC is not
clear. In this study, we found that the expression level of
miR-199b was inversely correlated with K-Ras mutations
in human NSCLC specimens and NSCLC cell lines. In
addition, in vitro data show that miR-199b expression
was inhibited by overexpression of mutant K-Ras and
increased by silencing of mutant K-Ras in NSCLC cells,
suggesting that mutant K-Ras negatively regulates
miR-199b expression in NSCLC. This is the first study
to show direct evidence that downregulated expression
levels of miR-199b are caused by K-Ras mutation in
NSCLC.
Next, we elucidated the mechanism by which mutant
K-Ras suppresses miR-199b expression. A previous study
showed that promoter methylation suppresses the
expression of miR-199b in solid cancers [24]. Here, we
showed that demethylation drug treatment causes res-
toration of miR-199b expression in K-Ras mutant
NSCLC cells, and mutant K-Ras-dependent inhibition of
miR-199b expression was abolished by demethylation
drug treatment in NSCLC cells, suggesting that
decreased expression of miR-199b in K-Ras mutant
NSCLC cells was associated with the methylation status
of the miR-199b promoter. In addition, our data showed
that overexpression of mutant K-Ras increased the
methylation of the miR-199b promoter in NSCLC cells,
whereas silencing of mutant K-Ras decreased the methy-
lation of the miR-199b promoter. These findings
strongly suggest that mutant K-Ras suppresses miR-199b
expression by increasing DNA methylation at the
miR-199b promoter in NSCLC cells. However, the
detailed mechanism of how mutant K-Ras regulates the
methylation of the miR-199b promoter will need to be
studied in the future.
Here, we also provide multiple evidences for the role
of miR-199b in regulating K-Ras-driven lung tumorigen-
esis and progression. K-Ras-mutant cancers are among
the most difficult to treat; they are associated with poor
patient survival [25]. Our data show that mutant K-Ras
suppresses miR-199b expression and that inhibition of
miR-199b stimulates NSCLC growth and metastasis.
Congruently, miR-199b restoration dramatically sup-
pressed K-Ras mutation-driven lung tumorigenesis, as
well as K-Ras-mutated NSCLC growth and metastasis.
These findings indicate that K-Ras mutant-mediated
tumorigenesis and progression are partly dependent on
the inhibition of miR-199b expression in the lungs. Add-
itionally, these findings indicate that restoration of
miR-199b is a useful strategy for treating K-Ras-mutated
NSCLC. This study is the first report to show that de-
creased expression of miR-199b is involved in K-Ras
mutation-driven lung tumorigenesis and progression.
Furthermore, we evaluated the anticancer mechanism
of miR-199b. Attempts to therapeutically target mem-
bers of RAS pathways, such as PI3K/Akt, RAF, MEK and
ERK, have yielded mixed results. This has led to the
current wave of multiagent trials (REFS) [8]. Evidence
shows that simultaneous inactivation of either of the two
pathways could be a strategy for the treatment of
a b
c
Fig. 5 Overexpression of miR-199b simultaneously suppresses the activation of Akt and ERK signaling pathways both in vitro and in vivo. a
Overexpression of miR-199b inhibited Akt and ERK signaling and stimulated apoptosis in A549 and H2122 NSCLC cell lines with K-Ras mutations.
The indicated cells were transfected with negative oligonucleotide controls or miR-199b mimics. After 72 h of transfection, cells were subjected to
Western blot analysis. b Aerosol delivery of miR-199b inhibited the Akt and ERK signaling pathways and stimulated apoptosis in lung tumors of K-
RasLA1 transgenic mice. The indicated proteins were detected using immunohistochemistry, and the apoptotic cells were detected using TUNEL
assay. c Inhibition of miR-199b activated Akt and ERK signaling. The indicated cells were transfected with negative oligonucleotide controls (NC)
or antisense nucleotides of miR-199b. After 72 h of transfection, cells were subjected to Western blot analysis
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K-Ras-mutated NSCLC. For example, Engelman et al.
reported that treatment of K-Ras-mutant mice with a
single inhibitor of the Akt or ERK pathway led to only
modest tumor regression. However, combination treat-
ment of Akt and ERK signaling inhibitors induced mark-
edly synergistic tumor regression [26]. miR-199b
significantly inhibits both PI3K/Akt and ERK signaling
activation in vitro and in vivo, suggesting that miR-199b
exerts its anticancer function through the simultaneous
inhibition of both Akt and ERK signaling in NSCLC.
Finally, we elucidated the mechanism by which miR-199b
inhibits the Akt and ERK signaling pathways in NSCLC
cells. Recent studies have shown that one single miRNA
plays its role through strongly influencing a specific signal-
ing pathway by simultaneously targeting multiple compo-
nents of that specific signaling pathway. For example, Fang
et al. reported that increased miR-582-3p expression in-
duces lung cancer recurrence through activating Wnt/β-ca-
tenin signaling by simultaneously inhibiting multiple
inhibitors of Wnt/β-catenin signaling, such as AXIN2,
DKK3 and SFRP1 [27]. Lin et al. reported that miR-135b
activates the hippo pathway by targeting multiple key com-
ponents of the pathway, including LATS2, NDR2 and
LTS1, to significantly stimulate lung cancer metastasis [28].
Here, we identified a series of novel target genes of
miR-199b that belong to PI3K/Akt and ERK signaling path-
ways, including K-Ras, PIK3R1, Akt1, Rheb1 and KSR2.
K-Ras is an upstream regulator of PI3K/Akt and ERK sig-
naling, and mutations in K-Ras lead to the activation of
these two oncogenic pathways in NSCLC [29]. PIK3R1,
Akt1, and Rheb1 have been identified as important compo-
nents of PI3K/Akt signaling activation, and they have been
suggested as therapeutic targets in lung cancer treatment
[12, 30, 31]. Finally, KSR2 is an activator of ERK signaling
[32–34], and its overexpression stimulates tumor cell trans-
formation [35]. These findings suggest that miR-199b in-
hibits the PI3K/Akt and ERK pathways by simultaneously




Fig. 6 Mutant K-Ras inhibits miR-199b expression in NSCLC cells by stimulating DNA methylation of the miR-199b promoter. a Demethylation
agent treatment increased miR-199b expression in K-Ras-mutated NSCLC cell lines. H2122 and A549 cells were treated with the indicated
concentration of 5-azacytidine (5`-aza) for 12 days. Next, they were subjected to miR-199b expression analysis. Cell culture medium was changed
every third day. b Demethylation agent treatment abolished mutant K-Ras overexpression-induced inhibition of miR-199b expression. H1975 cells
were transfected with mutant K-Ras (G12D) expression plasmid or empty vectors. After 24 h of transfection, cells were treated with or without
5 μM 5`-aza for 6 days. Then, cells were subjected to qRT-PCR and Western blot analysis. c Mutant K-Ras increased DNA methylation of the miR-
199b promoter in H1975 cells. Cells were transfected with K-Ras (G12D). After 96 h of transfection, cells were subjected to bisulfite sequencing
analysis. d Silencing of K-Ras inhibits DNA methylation of the miR-199b promoter in the K-Ras mutated cell H2122. Cells were transfected with K-
Ras shRNA expression vector or scramble vector. After 96 h of transfection, cells were subjected to bisulfite sequencing analysis. e A schematic
model of lung tumorigenesis regulation and the progression of K-Ras-mutated NSCLC by the miR-199b regulatory axis
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Conclusion
In conclusion, our findings suggest that mutant K-Ras
stimulates lung tumorigenesis and progression partly
through the inhibition of miR-199b expression by pro-
moting miR-199b promoter methylation. Restoration of
miR-199b may be a useful strategy for inhibiting K-Ras
mutation-driven lung tumorigenesis and for treating
K-Ras-mutated NSCLC. miR-199b plays an anticancer
role by simultaneously inhibiting the Akt and ERK path-
ways by directly targeting several components of the Akt
and ERK pathways in NSCLC (Fig. 6e).
Additional file
Additional file 1: Table S1 Primer sequences used for qRT-PCR. Figure
S1 Expression of K-Ras in NSCLC cells that overexpressed or silenced K-
Ras. a shRNA of K-Ras significantly suppressed K-Ras expression in NSCLC
cells. Indicated cells were transfected with indicated shRNA of K-Ras. After
72 hours of transfection, cells were subjected to Western blot analysis. b
Transfection of K-Ras (G12D) expression vector significantly increased K-
Ras (G12D) expression in NSCLC cells. Indicated cells were transfected
with K-Ras (G12D) expression plasmid. After 72 hours of transfection, cells
were subjected to Western blot analysis. Figure S2 Expression of miR-
199b in NSCLC cells that overexpressed or inhibited miR-199b. a H522
and H1975 cells were transfected with indicated negative oligonucleo-
tides control (NC) or antisense nucleotides of miR-199 (ASO miR-199b).
After 72 hours of transfection, cells were subjected to qRT-PCR analysis. b
miR-199b was significantly decreased in stably expressing miR-199b anti-
sense H522 cells. c A549 and H2122 cells were transfected with indicated
negative oligonucleotides control (NC) or miR-199 mimics. After 72 hours
of transfection, cells were subjected to qRT-PCR analysis. d miR-199b level
was significantly increased in stably expressing miR-199b A549cells. Fig-
ure S3 Aerosol delivery of miR-199b to the lung of mice. a Gene delivery
efficiency of PCAmHn as a gene carrier. Delivery efficiency of PCAmHn as a
gene carrier was evaluated using PCAmHn/green fluorescent protein
(GFP) expression plasmid complex. ICR mice were exposed to aerosol
containing PCAmHn/GFP expression plasmid complex or GFP expression
plasmid only for 30 minuets, and 72 hours post-treatment, the mice were
sacrificed for delivery efficiency assay. Green signals indicated that most
of the delivered GFP was efficiently trasfected into lung. b miR-199b ex-
pression was measured in the lung tissue of K-RasLA1 transgenic mice.
Control mice were exposed to the gene carrier only (carrier); Vector
group mice were exposed to vector mixed with the gene carrier (vector);
miR-199b group mice were exposed to the miR-199b expression plasmid
mixed with the gene carrier (miR-199b). Figure S4 The protein levels of
miR-199b candidate targets in NSCLC cells and the lungs of K-RasLA1
transgenic mice. a. The expression levels of the indicated proteins in Fig.
4e were quantified using image J software. b. The expression levels of
the indicated proteins in Fig. 4f were quantified using image J software.
*,p<0.05 compare to carrier control; **, p<0.01 compared to carrier con-
trol; #, p<0.05 compared to vector control; ##, p<0.01 compared to carrier
control. Figure S5 The protein levels of Akt and ERK signaling pathway
related genes in NSCLC cells. a. The expression levels of the indicated
proteins in Fig. 5a were quantified using image J software. b. The expres-
sion levels of the indicated proteins in Fig. 5c were quantified using
image J software. (PPTX 820 kb)
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